Drugs / Ximelagatran
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00206063 | Aug 1999 → Jun 2004 | — | AstraZeneca | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00206089 | Sep 2005 → Aug 2006 | venous thromboembolism | AstraZeneca | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ximelagatran | “melagatran injection followed by ximelagatran tablets” NCT00206089 ↗ |
| Known as | EXANTA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00206063 ↗ |
| Known as | H 376/95 | ChEMBL registry synonym — accepted as the source's own label CHEMBL522038 ↗ |
| Action | Inhibit | “oral direct thrombin inhibitor” NCT00206063 ↗1“Thrombin inhibitor” CHEMBL522038 ↗ |
| Modality | Small molecule | — CHEMBL522038 ↗ |
| Route | Oral | “Oral Direct Thrombin Inhibitor Ximelagatran” NCT00206063 ↗ |
| Target | F2 | “Thrombin inhibitor” CHEMBL522038 ↗ |